We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.

AusPAR: Pazopanib hydrochloride

Australian Public Assessment Report

AusPAR

AusPAR: Pazopanib hydrochloride [PDF, 687.46 KB]

AusPAR: Pazopanib hydrochloride [Word, 1.14 MB]

Attachment: Product Information: Pazopanib hydrochloride [PDF, 348.14 KB]

Attachment: Product Information: Pazopanib hydrochloride [Word, 296.18 KB]

Attachment: Extract from Clinical Evaluation Report: Pazopanib hydrochloride [PDF, 628.19 KB]

Attachment: Extract from Clinical Evaluation Report: Pazopanib hydrochloride [Word, 1.04 MB]

Device/Product Name

Votrient

Active ingredients

Pazopanib hydrochloride

AusPAR Date

25 February 2013

Published

19 July 2013

Submission Number

PM-2011-01972-3-4

Submission Type

Extension of indications

Decision

Approved